Hans K Hasselbalch

Hans K Hasselbalch

Clinical Professor

Member of:

  • Internal Medicine: Haematology


Publication year:
All
91 - 100 out of 133Page size: 10
Sort by: Title
  1. Published

    Rationaler for behandling med januskinase 1/2-hæmning af svært syge patienter med COVID-19-pneumoni

    Hasselbalch, Hans Carl, Poulsen, Anne, Skov, V., Kjær, L., Nielsen, C. H. & Poulsen, T. D., 2020, In: Ugeskrift for Laeger. 182, 25, 9 p., V04200234.

    Research output: Contribution to journal › Review › Research › peer-review

  2. Published

    Recombinant Interferon-β in the Treatment of Polycythemia Vera and Related Neoplasms: Rationales and Perspectives

    Hasselbalch, Hans Carl, Skov, V., Kjær, L., Larsen, Morten Kranker, Knudsen, T. A., Lucijanić, M. & Kusec, R., 2022, In: Cancers. 14, 22, 5495.

    Research output: Contribution to journal › Journal article › Research › peer-review

  3. Published

    Response to pegylated interferon in a COVID-19 positive male with metastatic jejunal neuroendocrine tumor treated with everolimus

    Frankel, A. E., Yip, W. C., Naik, E. & Hasselbalch, Hans Carl, 2021, In: Clinical Case Reports. 9, 6, e04218.

    Research output: Contribution to journal › Journal article › Research › peer-review

  4. Published

    Response to pegylated interferon in a COVID-19–positive elderly woman with primary myelofibrosis treated with ruxolitinib

    Frankel, A. E., Reddy, R., DeSuza, K. R., Deeb, K., Carlin, A. F., Smith, D., Xie, Y., Naik, E., Silver, R. T. & Hasselbalch, Hans Carl, 2021, In: Clinical Case Reports. 9, 4, p. 2228-2235 8 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  5. Published

    Retinal drusen in patients with chronic myeloproliferative blood cancers are associated with an increased proportion of senescent T cells and signs of an aging immune system

    Liisborg, C., Skov, V., Kjær, L., Hasselbalch, Hans Carl & Sørensen, Torben Lykke, 2021, In: Aging. 13, 24, p. 25763—25777

    Research output: Contribution to journal › Journal article › Research › peer-review

  6. Published

    Revisiting Circulating Extracellular Matrix Fragments as Disease Markers in Myelofibrosis and Related Neoplasms

    Hasselbalch, Hans Carl, Junker, P., Skov, V., Kjær, L., Knudsen, T. A., Larsen, Morten Kranker, Holmström, M. O., Andersen, Mads Hald, Jensen, C., Karsdal, M. A. & Willumsen, N., 2023, In: Cancers. 15, 17, 47 p., 4323.

    Research output: Contribution to journal › Review › Research › peer-review

  7. Published

    Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups

    Gisslinger, H., Klade, C., Georgiev, P., Krochmalczyk, D., Gercheva-kyuchukova, L., Egyed, M., Rossiev, V., Dulicek, P., Illes, A., Pylypenko, H., Sivcheva, L., Mayer, J., Yablokova, V., Krejcy, K., Hasselbalch, Hans Carl, Kralovics, R. & Kiladjian, J., 2020, In: HemaSphere. 4, 6, 4 p., e485.

    Research output: Contribution to journal › Journal article › Research › peer-review

  8. Published

    Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study

    Gisslinger, H., Klade, C., Georgiev, P., Krochmalczyk, D., Gercheva-Kyuchukova, L., Egyed, M., Rossiev, V., Dulicek, P., Illes, A., Pylypenko, H., Sivcheva, L., Mayer, J., Yablokova, V., Krejcy, K., Grohmann-Izay, B., Hasselbalch, H. C., Kralovics, R., Kiladjian, J. J., Bauer, F., Berbec, N. & 41 others, Besses Raebel, C., Borbenyi, Z., Bumbea, H., Buxhofer-Ausch, V., Calbecka, M., Cayssials-Caylus, E., Cazzola, M., Cerna, O., Cucuianu, A., Dima, D. M., Forjan, E., Gheorghita, E., Greil, R., Hatalova, A., Hrubisko, M., Jakucs, J., Kaplan, P., Klymenko, S., Koschmieder, S., Lazaroiu, M., Lysa, T., Masliak, Z., Masszi, T., Mihaylov, G., Myasnikov, A., Platzbecker, U., Puyade, M., Rey, J., Roy, L., Schwarz, J., Skotnicki, A., Sokolova, I., Soroka-Wojtaszko, M., Starzak-Gwozdz, J., Stoeva, V., Torregrosa-Diaz, J. M., Vallova, A., Volodicheva, E., Warzocha, K., Willenbacher, E. & Wolf, D., 2020, In: The Lancet Haematology. 7, 3, p. e196-e208 13 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  9. Published

    Ruxolitinib treatment reduces monocytic superoxide radical formation without affecting hydrogen peroxide formation or systemic oxidative nucleoside damage in myelofibrosis

    Bjørn, M. E., Brimnes, M. K., Gudbrandsdottir, S., Andersen, C. L., Poulsen, Henrik Enghusen, Henriksen, T., Hasselbalch, Hans Carl & Nielsen, Claus Henrik, Oct 2019, In: Leukemia and Lymphoma. 60, 10, p. 2549-2557 9 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  10. Published

    Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis

    Mikkelsen, Stine Ulrik, Kjaer, L., Bjørn, M. E., Knudsen, T. A., Sørensen, A. L., Andersen, Christen Bertel L, Bjerrum, O. W., Brochmann, N., Fassi, Daniel El , Kruse, T. A., Larsen, T. S., Mourits-Andersen, H. T., Nielsen, Claus Henrik, Pallisgaard, N., Thomassen, M., Skov, V. & Hasselbalch, Hans Carl, Aug 2018, In: Cancer Medicine. 7, 8, p. 3571-3581 11 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

Previous 1...6 7 8 9 10 11 12 13 14 Next

ID: 2849472